[go: up one dir, main page]

PE20160890A1 - Inhibidor de beta-lactamasa cristalina - Google Patents

Inhibidor de beta-lactamasa cristalina

Info

Publication number
PE20160890A1
PE20160890A1 PE2016000598A PE2016000598A PE20160890A1 PE 20160890 A1 PE20160890 A1 PE 20160890A1 PE 2016000598 A PE2016000598 A PE 2016000598A PE 2016000598 A PE2016000598 A PE 2016000598A PE 20160890 A1 PE20160890 A1 PE 20160890A1
Authority
PE
Peru
Prior art keywords
lactamase inhibitor
methyl
crystalline beta
theta
refers
Prior art date
Application number
PE2016000598A
Other languages
English (en)
Inventor
Stefano Biondi
Alessandro Lamonica
Marco Forzatti
Original Assignee
Allecra Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Sas filed Critical Allecra Therapeutics Sas
Publication of PE20160890A1 publication Critical patent/PE20160890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere al compuesto cristalino 4,4-dioxido de (2S, 3S, 5R)-3-metil-3-((3-metil-1H-1,2,3-triazol-3-io-1-il)metil)-7-oxo-4-tia-1-azabiciclo[3.2.0]heptan-2-carboxilato de formula I caracterizado por un espectro XRPD que comprende 4 o mas picos con angulos 2(theta) de 8.82, 12.07, 14.43, 14.92, 16.26, 18.25, 19.06, 19.78, 20.82 y 23.52 +/- 0.1 grados 2(theta). Tambien se refiere a su proceso de preparacion, una composicion farmaceutica y un metodo de tratamiento. Dicho compuesto es un inhibidor beta-lactamasa y puede administrarse con un agente antibacteriano para la prevencion o tratamiento de una infeccion bacteriana
PE2016000598A 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina PE20160890A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound

Publications (1)

Publication Number Publication Date
PE20160890A1 true PE20160890A1 (es) 2016-08-25

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000598A PE20160890A1 (es) 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina

Country Status (14)

Country Link
US (2) US20160289245A1 (es)
EP (1) EP3066103A1 (es)
JP (2) JP7045795B2 (es)
KR (1) KR20160081964A (es)
CN (1) CN105873935B (es)
AU (1) AU2014345507B2 (es)
CA (1) CA2929199C (es)
CL (1) CL2016001097A1 (es)
EA (1) EA031348B1 (es)
GB (2) GB201319776D0 (es)
IL (1) IL245386A0 (es)
MX (1) MX2016005869A (es)
PE (1) PE20160890A1 (es)
WO (1) WO2015067787A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
CA2282461C (en) * 1997-12-29 2004-04-20 John D. Buynak 2-.beta.-substituted-6-alkylidene penicillanic acid derivatives as .beta.-lactamase inhibitors
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
US7687488B2 (en) * 2006-07-12 2010-03-30 Orchid Chemicals & Pharmaceuticals Ltd. 2-substituted methyl penam derivatives
BR112013012735B1 (pt) * 2010-11-25 2021-11-23 Allecra Therapeutics Gmbh Composição farmacêutica inibidora de ss-lactamase
WO2013169397A1 (en) * 2012-05-07 2013-11-14 The Regents Of The University Of California Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
WO2014179756A1 (en) * 2013-05-02 2014-11-06 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
CN107427526B (zh) * 2014-12-09 2021-08-03 华沙整形外科股份有限公司 涉及甾醇的化合物和方法

Also Published As

Publication number Publication date
MX2016005869A (es) 2017-01-05
US20160289245A1 (en) 2016-10-06
CL2016001097A1 (es) 2016-12-02
CN105873935B (zh) 2019-03-19
WO2015067787A1 (en) 2015-05-14
AU2014345507B2 (en) 2018-11-22
GB201319776D0 (en) 2013-12-25
CA2929199C (en) 2023-01-03
KR20160081964A (ko) 2016-07-08
EP3066103A1 (en) 2016-09-14
US11124526B2 (en) 2021-09-21
IL245386A0 (en) 2016-06-30
JP2021102642A (ja) 2021-07-15
US20190071456A1 (en) 2019-03-07
JP2016535054A (ja) 2016-11-10
JP7346485B2 (ja) 2023-09-19
JP7045795B2 (ja) 2022-04-01
CN105873935A (zh) 2016-08-17
EA201690963A1 (ru) 2016-10-31
EA031348B1 (ru) 2018-12-28
CA2929199A1 (en) 2015-05-14
GB201408643D0 (en) 2014-07-02
AU2014345507A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
EA201390198A1 (ru) Гетероциклическое соединение
CA2875877C (en) Syk inhibitors
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
MD4602B1 (ro) Inhibitori ai virusului hepatic C
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
NZ751197A (en) Compounds and methods of treating infections
WO2012083122A8 (en) Inhibitors of influenza viruses replication
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
NZ607580A (en) N-heteroaryl compounds
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
HK1211290A1 (en) Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
WO2014036502A3 (en) Tetracycline compounds
WO2014165107A3 (en) Mannose derivatives for treating bacterial infections
HK1222339A1 (zh) 金属-β-内酰胺酶的抑制剂
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
EA201491982A1 (ru) Антибактериальные хинолиновые производные
PH12016500577B1 (en) Piperazine derivatives and the use thereof as medicament
PE20141993A1 (es) Compuestos de benzotiazolona
SG10201901578UA (en) Processes for the preparation of pyrimidinylcyclopentane compounds

Legal Events

Date Code Title Description
FD Application declared void or lapsed